Aromasin

June 27, 2018June 27, 2018

Phase 3 Trial Testing Aromasin-Chidamide Combo for Advanced Breast Cancer Meets Primary Goal

News

Adding investigational therapy chidamide to Aromasin (exemestane) significantly delayed disease progression or death in patients with advanced breast cancer, results from a Phase 3 trial show. This means that the pivotal trial (NCT02482753) has ... Read more

January 4, 2017

Mutations in Estrogen Receptor May Predict Poor Outcomes in Specific Breast Cancer Patients

News

Mutations in the estrogen receptor (ESR1) are associated with worse outcomes in breast cancer patients treated with estrogen deprivation therapy in the form of the aromatase inhibitor Aromasin (exemestane), according to ... Read more

June 9, 2016June 9, 2016

Exemestane and Everolimus: Hormone and Biological Therapy Treatment Combination

News

Exemestane Exemestane, also known as Aromasin, is a type of oral, targeted cancer therapy called an aromatase inhibitor and works by a mechanism that stops the production of estrogen in ... Read more